Nanoscope Therapeutics Receives Fast Track Designation by the FDA for MCO-010 for the Treatment of Stargardt Disease

DALLAS, Jan. 30, 2023 -- (Healthcare Sales & Marketing Network) -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that the U.S. Food and Drug Administration ... Regenerative Medicine, Ophthalmology, FDA Nanoscope Therapeutics, Stargardt, optogenetic, gene therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news